Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial

This article has no abstract
Epistemonikos ID: e80c7c770fe3969e6c9c9e102e07398050f73abb
First added on: Feb 12, 2025